CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer

PUBT · 3d ago
CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer
  • CSPC Pharmaceutical’s SYS6090 (JMT108) won US FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer in patients who progressed on standard therapies.
  • Program backed by preclinical results, ongoing Phase 1 studies in China, ongoing Phase 1 studies in the US.
  • Drug targets PD-1 blockade with IL-15 pathway activation, aiming to improve immunotherapy response in “cold” MSS/pMMR tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300239), on August 26, 2026, and is solely responsible for the information contained therein.